KALV: KalVista Pharmaceuticals, Inc.
About
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.
Current Value
$9.001 Year Return
Current Value
$9.001 Year Return
Key Details
Market Cap
$440.88M
P/E Ratio
-2.56
1Y Stock Return
17.08%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
2.3
Strategies that include KALV
Stock's related to KALV
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| FATE | 43.71% | $248.29M | -11.02% | 0.00% |
| IDYA | 42.04% | $2.24B | -15.21% | 0.00% |
| ALLO | 41.38% | $444.50M | -24.82% | 0.00% |
| RCKT | 41.08% | $1.20B | -39.83% | 0.00% |
| PLRX | 40.45% | $778.32M | -9.55% | 0.00% |
| ATXS | 40.20% | $550.23M | +114.29% | 0.00% |
| FOLD | 39.94% | $2.84B | -11.52% | 0.00% |
| RYTM | 39.65% | $3.69B | +79.50% | 0.00% |
| SNDX | 39.59% | $1.35B | +2.87% | 0.00% |
| ALEC | 38.15% | $377.04M | -19.46% | 0.00% |
| ESTA | 37.98% | $968.33M | +54.98% | 0.00% |
| ONIT | 36.74% | $240.15M | +14.44% | 0.00% |
| DAWN | 35.09% | $1.36B | +13.42% | 0.00% |
| AXSM | 35.05% | $4.63B | +61.30% | 0.00% |
| KRYS | 34.69% | $5.12B | +75.65% | 0.00% |
| FARO | 34.65% | $486.17M | +40.51% | 0.00% |
| ZYME | 34.34% | $1.03B | +79.68% | 0.00% |
| PLUG | 34.27% | $1.75B | -46.14% | 0.00% |
| PGEN | 34.14% | $228.91M | -28.00% | 0.00% |
| RNA | 34.02% | $5.16B | +638.05% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LRN | -0.01% | $4.43B | +74.97% | 0.00% |
| MANU | -0.01% | $2.88B | -9.41% | 0.00% |
| LEU | 0.02% | $1.12B | +33.82% | 0.00% |
| FCN | -0.09% | $7.10B | -10.74% | 0.00% |
| SMC | -0.10% | $383.35M | +97.26% | 0.00% |
| WB | 0.10% | $1.41B | -16.20% | 0.00% |
| GO | 0.17% | $1.81B | -34.42% | 0.00% |
| CNC | 0.19% | $29.19B | -21.56% | 0.00% |
| ED | 0.23% | $33.59B | +7.16% | 3.43% |
| TKO | -0.24% | $10.62B | +67.14% | 0.00% |
| MESO | -0.24% | $1.23B | +347.11% | 0.00% |
| SSSS | -0.28% | - | - | 0.00% |
| UNH | -0.29% | $531.00B | +6.93% | 1.37% |
| HRL | 0.33% | $16.30B | -8.38% | 3.81% |
| HTHT | -0.35% | $11.34B | -0.47% | 0.00% |
| AMPY | 0.42% | $260.89M | +7.01% | 0.00% |
| APD | -0.44% | $72.92B | +18.69% | 2.14% |
| LUMO | -0.44% | $37.45M | +41.97% | 0.00% |
| TPST | 0.45% | $37.75M | -77.59% | 0.00% |
| POST | 0.46% | $6.45B | +28.40% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| VZ | -15.22% | $176.51B | +12.56% | 6.37% |
| UUU | -13.26% | $4.97M | -41.89% | 0.00% |
| MNR | -11.64% | $1.66B | -10.71% | 15.90% |
| MBI | -11.47% | $335.78M | +105.79% | 0.00% |
| CBOE | -11.25% | $21.46B | +15.84% | 1.11% |
| VZIO | -10.92% | $2.29B | +67.76% | 0.00% |
| CLX | -10.91% | $20.81B | +20.66% | 2.88% |
| ACHC | -10.39% | $3.45B | -48.91% | 0.00% |
| PEP | -10.28% | $215.02B | -6.60% | 3.35% |
| STG | -10.19% | $35.67M | +7.92% | 0.00% |
| PEG | -9.71% | $44.89B | +40.46% | 2.63% |
| WHLM | -9.69% | $17.64M | -29.34% | 0.00% |
| PG | -9.19% | $402.15B | +14.14% | 2.33% |
| KO | -9.16% | $269.63B | +7.86% | 3.07% |
| MOH | -7.93% | $16.16B | -21.56% | 0.00% |
| K | -7.84% | $27.77B | +52.50% | 2.79% |
| NOC | -7.73% | $71.54B | +4.23% | 1.60% |
| GIS | -7.50% | $34.85B | -2.91% | 3.78% |
| MVO | -7.50% | $106.15M | -22.78% | 16.78% |
| LNG | -7.45% | $49.37B | +24.99% | 0.82% |
ETF's related to KALV
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 46.72% | $6.58B | 0.35% |
| PTH | 46.24% | $143.31M | 0.6% |
| RSPA | 42.87% | $273.87M | 0% |
| GNOM | 41.25% | $70.59M | 0.5% |
| PBE | 40.45% | $258.53M | 0.58% |
| IWC | 40.42% | $933.99M | 0.6% |
| IWO | 39.82% | $12.56B | 0.24% |
| IBB | 38.84% | $6.66B | 0.45% |
| IWM | 38.54% | $75.73B | 0.19% |
| VTWO | 38.37% | $12.38B | 0.1% |
| XPH | 37.60% | $157.87M | 0.35% |
| ISCG | 37.46% | $640.00M | 0.06% |
| ARKG | 37.24% | $1.13B | 0.75% |
| KOMP | 37.12% | $2.09B | 0.2% |
| EES | 37.08% | $668.71M | 0.38% |
| IJT | 36.52% | $6.64B | 0.18% |
| SLYG | 36.51% | $3.69B | 0.15% |
| PSC | 36.20% | $702.17M | 0.38% |
| VBK | 36.10% | $19.31B | 0.07% |
| VIOO | 35.95% | $3.12B | 0.1% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| AGZD | 0.44% | $142.76M | 0.23% |
| HDRO | 0.52% | $164.26M | 0.3% |
| XBIL | -0.79% | $637.70M | 0.15% |
| KLIP | -1.95% | $125.85M | 0.93% |
| FBY | 2.03% | $127.69M | 0.99% |
| MINT | -2.15% | $11.62B | 0.35% |
| FTXG | 2.60% | $30.81M | 0.6% |
| BOXX | -2.66% | $4.43B | 0.1949% |
| SGOV | 2.83% | $27.53B | 0.09% |
| FXI | 2.86% | $8.09B | 0.74% |
| CPER | 2.89% | $159.52M | 0.97% |
| DBMF | 3.08% | $1.02B | 0.85% |
| IYK | -3.16% | $1.30B | 0.4% |
| GCC | -3.21% | $133.23M | 0.55% |
| JUCY | 3.35% | $324.29M | 0.6% |
| MSOS | 3.44% | $632.80M | 0.83% |
| FLRN | -3.50% | $2.33B | 0.15% |
| UNG | -3.52% | $908.80M | 1.06% |
| KCCA | -3.57% | $220.51M | 0.87% |
| FLTR | 3.60% | $1.79B | 0.14% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -32.17% | $388.04M | 1.43% |
| VIXY | -16.53% | $195.31M | 0.85% |
| DBA | -13.98% | $755.88M | 0.93% |
| WEAT | -12.63% | $120.27M | 0.28% |
| UUP | -12.20% | $309.25M | 0.77% |
| USDU | -12.17% | $201.97M | 0.5% |
| CTA | -8.69% | $350.27M | 0.78% |
| TPMN | -8.00% | $40.60M | 0.65% |
| USCI | -8.00% | $185.47M | 1.07% |
| SOYB | -7.37% | $27.32M | 0.22% |
| CORN | -6.81% | $61.12M | 0.2% |
| CLOI | -6.40% | $715.40M | 0.4% |
| COMT | -6.06% | $829.06M | 0.48% |
| EQLS | -5.98% | $76.08M | 1% |
| GSG | -5.89% | $914.42M | 0.75% |
| CANE | -5.86% | $17.72M | 0.29% |
| DBO | -5.83% | $217.57M | 0.77% |
| BCI | -5.68% | $1.20B | 0.26% |
| PDBC | -5.45% | $4.40B | 0.59% |
| FTGC | -5.38% | $2.17B | 1.02% |
News
Yahoo
CAMBRIDGE, Mass. & SALISBURY, England, November 12, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences:
Yahoo
KalVista Pharmaceuticals ( (KALV) ) has provided an update. KalVista Pharmaceuticals has secured a significant up to $184 million synthetic royalty financing deal with DRI Healthcare Trust to fund the commercialization of sebetralstat, a novel oral therapy for hereditary angioedema (HAE). The agreement includes an initial $100 million upfront payment, potential milestone payments, and a tiered royalty structure based on global net sales. This strategic move strengthens KalVista’s financial posit
Yahoo
CAMBRIDGE, Mass. & SALISBURY, England, November 05, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted twelve newly-hired employees inducement options to purchase an aggregate of 78,000 shares of KalVista common stock on November 1, 2024 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Finnhub
By Sabela Ojea Shares of KalVista Pharmaceuticals climbed after the company said it expects to receive $179 million from a synthetic royalty financing agreement with DRI Healthcare Trust, and $55...
Yahoo
DRI Healthcare Trust Acquires Royalty Stake in Global Sales of Sebetralstat
Yahoo
CAMBRIDGE, Mass. & SALISBURY, England, November 04, 2024--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) ("KalVista") today announced the pricing of an underwritten offering of 5,500,000 shares of its common stock at a price of $10.00 per share to certain investors (the "Offering"). The gross proceeds to KalVista from the Offering are expected to be $55 million, before deducting underwriting discounts, commissions and other offering expenses payable by KalVista.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.